Enzymatica has published its year-end report, revealing an operating result of SEK -48.1 million and net sales of SEK 50.9 million for the full year. While sales increased in Sweden, the order intake from partners in other markets has been below expectations. To reverse this trend, MDR certification and study result will be crucial factors, according to CEO Claus Egstrand. 

Read the full article at biostock.se:

https://www.biostock.se/en/2024/02/enzymaticas-partners-await-mdr-certification-and-study-results/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/enzymatica-ab/r/biostock-enzymatica-s-partners-await-mdr-certification-and-study-results,c3935517

(c) 2024 Cision. All rights reserved., source Press Releases - English